Influence of antipsychotics on mortality in schizophrenia: Systematic review

Schizophrenia Research

Volumn 113, Issue 1, 2009, Pages 1-11

  Weinmann, Stefan ^a   Read, John ^b   Aderhold, Volkmar ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Antipsychotic agents; Mortality; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; ZUCLOPENTHIXOL;

ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; DELUSIONAL DISORDER; DISEASE SEVERITY; HEART ARREST; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LONG TERM EXPOSURE; MORTALITY; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 67649854909     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.05.018     Document Type: Article

References (43)

1. Barbui C., Nose M., Mazzi M.A., Thornicroft G., Schene A., Becker T., Bindman J., Leese M., Helm H., Koeter M., Weinmann S., and Tansella M. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology 21 (2006) 355-362
2. Bralet M.C., Yon V., Loas G., and Noisette C. Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale 26 (2000) 32-41
3. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., and Hennekens C.H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry 65 Suppl 7 (2004) 4-18
4. Catts V.S., Catts S.V., O'Toole B.I., and Frost A.D. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatrica Scandinavica 117 (2008) 323-336
5. Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain. Journal of Clinical Psychiatry 68 Suppl 12 (2007) 12-17
6. Correll C.U., Frederickson A.M., Kane J.M., and Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry 67 (2006) 575-583
7. Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., Rosenheck R., Davis S.M., Hsiao J.K., Stroup T.S., and Lieberman J.A. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105 (2008) 175-187
8. Dean C.E., and Thuras P.D. Mortality and tardive dyskinesia: long-term study using the US National Death Index. British Journal of Psychiatry 194 (2009) 360-364
9. de Haan L., Booij J., Lavalaye J., van A.T., and Linszen D. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl) 183 (2006) 500-505
10. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. Journal of Clinical Psychopharmacology 28 (2008) 125-131
11. Enger C., Weatherby L., Reynolds R.F., Glasser D.B., and Walker A.M. Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous & Mental Disease 192 (2004) 19-27
12. Haukka J., Tiihonen J., Harkanen T., and Lonnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety 17 (2008) 686-696
13. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., Evins A.E., Cather C., and Goff D.C. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Journal of Clinical Psychiatry 66 (2005) 1116-1121
14. Hennessy S., Bilker W.B., Knauss J.S., Margolis D.J., Kimmel S.E., Reynolds R.F., Glasser D.B., Morrison M.F., and Strom B.L. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. British Medical Journal 325 (2002) 1070
15. Janssen B., Weinmann S., Berger M., and Gaebel W. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophrenia Bulletin 30 (2004) 1023-1033
16. Joseph K.S., Blais L., Ernst P., and Suissa S. Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. British Medical Journal 312 (1996) 79-82
17. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., and Lehtinen V. Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 188 (2006) 122-127
18. Kilian R., Becker T., Kruger K., Schmid S., and Frasch K. Health behavior in psychiatric in-patients compared with a German general population sample. Acta Psychiatrica Scandinavica 114 (2006) 242-248
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
20. Loas G., Azi A., Noisette C., and Yon V. [Mortality among chronic schizophrenic patients: a prospective 14-year follow-up study of 150 schizophrenic patients]. [French]. Encephale 34 (2008) 54-60
21. McGovern P.G., Pankow J.S., Shahar E., Doliszny K.M., Folsom A.R., Blackburn H., and Luepker R.V. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. New England Journal of Medicine 334 (1996) 884-890
22. Mitchell A.J., and Malone D. Physical health and schizophrenia. Current Opinion in Psychiatry 19 (2006) 432-437
23. Montout C., Casadebaig F., Lagnaoui R., Verdoux H., Philippe A., Begaud B., and Moore N. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research 57 (2002) 147-156
24. Morgan M.G., Scully P.J., Youssef H.A., Kinsella A., Owens J.M., and Waddington J.L. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Research 117 (2003) 127-135
25. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
26. Newcomer J.W., Meyer J.M., Baker R.A., Eudicone J.M., Pikalov A., Vester-Blokland E., McQuade R.D., Crandall D.T., Carson W.H., Marcus R.N., and L'italien G. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 106 (2008) 300-307
27. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., and King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Archives of General Psychiatry 64 (2007) 242-249
28. Rabinowitz J., Levine S.Z., and Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophrenia Research 88 (2006) 96-101
29. Ray W.A. Observational studies of drugs and mortality. New England Journal of Medicine 353 (2005) 2319-2321
30. Ray W.A., Chung C.P., Murray K.T., Hall K., and Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360 (2009) 225-235
31. Ray W.A., Meredith S., Thapa P.B., Meador K.G., Hall K., and Murray K.T. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 58 (2001) 1161-1167
32. Reist C., Mintz J., Albers L.J., Jamal M.M., Szabo S., and Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. Journal of Clinical Psychopharmacology 27 (2007) 46-51
33. Saha S., Chant D., and McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Archives of General Psychiatry 64 (2007) 1123-1131
34. Salokangas R.K. Gender and the use of neuroleptics in schizophrenia. Schizophrenia Research 66 (2004) 41-49
35. Schneeweiss S., and Avorn J. Antipsychotic agents and sudden cardiac death-how should we manage the risk?. New England Journal of Medicine 360 (2009) 294-296
36. Schooler N.R. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatrica Scandinavica 380 (1994) 21-26
37. Selten J.P., Veen N.D., Hoek H.W., Laan W., Schols D., van der Tweel I., Feller W., and Kahn R.S. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophrenia Research 97 (2007) 79-87
38. Straus S.M., Bleumink G.S., Dieleman J.P., van der Lei J., 't Jong G.W., Kingma J.H., Sturkenboom M.C., and Stricker B.H. Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine 164 (2004) 1293-1297
39. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., and Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association 283 (2000) 2008-2012
40. Tiihonen J., Walhbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P., Volavka J., and Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333 (2006) 224 Electronic publication 2006 July 6
41. Waddington J.L., Youssef H.A., and Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173 (1998) 325-329
42. Walker A.M., Lanza L.L., Arellano F., and Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 8 (1997) 671-677
43. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847